Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|October 2, 2004
- Pharmaceutical Technology-10-02-2004
- Volume 28
- Issue 10
In The Spotlight-October 2004
Pharmaceutical Science & Technology Innovations
Articles in this issue
about 22 years ago
A Novel Freeze Pelletization Technique for Preparing Matix Pelletsabout 22 years ago
Aseptic Processing: A Review of Current Industry Practiceabout 22 years ago
Can Inserts Be Improved?about 22 years ago
Drug Development Linked More Closely to Diagnosticsabout 22 years ago
October 2004about 22 years ago
The High Price of SuccessRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
2
FDA Allegedly Shelves Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5